Camila González-Beiras1,2, August Kapa3, Marti Vall-Mayans4, Raymond Paru3, Sergi Gavilán1, Wendy Houinei5, Sibauk Bieb5, Sergi Sanz1, Rosario Martins6, Oriol Mitjà1,3,7. 1. Barcelona Institute for Global Health, Hospital Clinic, University of Barcelona, Spain. 2. Global Public Health PhD Program, Institute of Hygiene and Tropical Medicine, Nova University of Lisbon, Portugal. 3. Lihir Medical Centre-International SOS, Newcrest Mining, Lihir Island, Papua New Guinea. 4. Sexually Transmitted Infections Unit, Hospital Vall d'Hebron, Barcelona, Spain. 5. Disease Control Branch, National Department of Health, Port Moresby, Papua New Guinea. 6. Global Health and Tropical Medicine, Institute of Hygiene and Tropical Medicine, Nova University of Lisbon, Portugal. 7. School of Medicine and Health Sciences, University of Papua New Guinea, Port Moresby.
Abstract
BACKGROUND: Haemophilus ducreyi (HD) and Treponema pallidum subspecies pertenue (TP) are major causative agents of cutaneous ulcer (CU) in the tropics. Azithromycin is recommended to treat sexually transmitted HD infections and has good in vitro activity against HD strains from both genital and skin ulcers. We investigated the efficacy of oral single-dose azithromycin on HD-CU. METHODS: We conducted a community-based cohort study in Lihir Island, Papua New Guinea, from October 2014 through May 2016. Consenting patients with skin ulcers >1 cm in diameter were eligible for this study and had collected a lesional swab for polymerase chain reaction (PCR). All participants were treated with single-dose azithromycin (30 mg/kg) and were followed up for assessment of clinical resolution. We retrospectively classified patients according to PCR results into HD, TP, and PCR-negative groups. The primary endpoint was healing rates of HD-CU at 14 days after treatment. RESULTS: We obtained full outcome data from 246 patients; 131 (53.3%) were HD PCR positive, 37 (15.0%) were TP positive, and 78 (31.7%) were negative for all tests. Healing rates were 88.5% (95% confidence interval [CI], .82-.93) in the HD group, 78.4% [95% CI, .63-.89] in the TP group, and 74.4% (95% CI, .64-.83) in the PCR-negative group. If we included the participants with improved ulcers, the healing rates increased to 94.7%, 97.3%, and 89.7% respectively. HD cases classified as not healed all converted to HD-negative PCR. CONCLUSIONS: Based upon clinical resolution and PCR conversion to HD negative, a single oral dose of azithromycin is efficacious for the treatment of HD-CU. These results have implications for the treatment of individual patients and for the use of antibiotics in public health strategies to control CU in the tropics.
BACKGROUND: Haemophilus ducreyi (HD) and Treponema pallidum subspecies pertenue (TP) are major causative agents of cutaneous ulcer (CU) in the tropics. Azithromycin is recommended to treat sexually transmitted HD infections and has good in vitro activity against HD strains from both genital and skin ulcers. We investigated the efficacy of oral single-dose azithromycin on HD-CU. METHODS: We conducted a community-based cohort study in Lihir Island, Papua New Guinea, from October 2014 through May 2016. Consenting patients with skin ulcers >1 cm in diameter were eligible for this study and had collected a lesional swab for polymerase chain reaction (PCR). All participants were treated with single-dose azithromycin (30 mg/kg) and were followed up for assessment of clinical resolution. We retrospectively classified patients according to PCR results into HD, TP, and PCR-negative groups. The primary endpoint was healing rates of HD-CU at 14 days after treatment. RESULTS: We obtained full outcome data from 246 patients; 131 (53.3%) were HD PCR positive, 37 (15.0%) were TP positive, and 78 (31.7%) were negative for all tests. Healing rates were 88.5% (95% confidence interval [CI], .82-.93) in the HD group, 78.4% [95% CI, .63-.89] in the TP group, and 74.4% (95% CI, .64-.83) in the PCR-negative group. If we included the participants with improved ulcers, the healing rates increased to 94.7%, 97.3%, and 89.7% respectively. HD cases classified as not healed all converted to HD-negative PCR. CONCLUSIONS: Based upon clinical resolution and PCR conversion to HD negative, a single oral dose of azithromycin is efficacious for the treatment of HD-CU. These results have implications for the treatment of individual patients and for the use of antibiotics in public health strategies to control CU in the tropics.
Authors: Isabelle Leduc; Kate R Fortney; Diane M Janowicz; Beth Zwickl; Sheila Ellinger; Barry P Katz; Huaiying Lin; Qunfeng Dong; Stanley M Spinola Journal: Infect Immun Date: 2019-06-20 Impact factor: 3.441
Authors: Lucy N John; Camila G Beiras; Wendy Houinei; Monica Medappa; Maria Sabok; Reman Kolmau; Eunice Jonathan; Edward Maika; James K Wangi; Petra Pospíšilová; David Šmajs; Dan Ouchi; Iván Galván-Femenía; Mathew A Beale; Lorenzo Giacani; Bonaventura Clotet; Eric Q Mooring; Michael Marks; Martí Vall-Mayans; Oriol Mitjà Journal: N Engl J Med Date: 2022-01-06 Impact factor: 91.245
Authors: Abdul Aziz Abdulai; Patrick Agana-Nsiire; Frank Biney; Cynthia Kwakye-Maclean; Sardick Kyei-Faried; Kwame Amponsa-Achiano; Shirley Victoria Simpson; George Bonsu; Sally-Ann Ohene; William Kwabena Ampofo; Yaw Adu-Sarkodie; Kennedy Kwasi Addo; Kai-Hua Chi; Damien Danavall; Cheng Y Chen; Allan Pillay; Sergi Sanz; Ye Tun; Oriol Mitjà; Kingsley Bampoe Asiedu; Ronald C Ballard Journal: PLoS Negl Trop Dis Date: 2018-03-22
Authors: Joseph W S Timothy; Mathew A Beale; Emerson Rogers; Zeela Zaizay; Katherine E Halliday; Tarnue Mulbah; Romeo K Giddings; Stephen L Walker; Nicholas R Thomson; Karsor K Kollie; Rachel L Pullan; Michael Marks Journal: Emerg Infect Dis Date: 2021-04 Impact factor: 6.883
Authors: Brad Griesenauer; Camila González-Beiras; Katherine R Fortney; Huaiying Lin; Xiang Gao; Charmie Godornes; David E Nelson; Barry P Katz; Sheila A Lukehart; Oriol Mitjà; Qunfeng Dong; Stanley M Spinola Journal: mBio Date: 2021-01-12 Impact factor: 7.867
Authors: Jacob C Grant; Camila González-Beiras; Kristen M Amick; Kate R Fortney; Dharanesh Gangaiah; Tricia L Humphreys; Oriol Mitjà; Ana Abecasis; Stanley M Spinola Journal: Clin Infect Dis Date: 2018-11-13 Impact factor: 20.999
Authors: Jarne M van Hattem; Tessa J C Langeveld; Sylvia M Bruisten; Marion Kolader; Martin P Grobusch; Henry J C de Vries; Godelieve J de Bree Journal: PLoS Negl Trop Dis Date: 2018-04-12